Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round

Pulnovo Medical has successfully completed an oversubscribed $100 million strategic financing round, with Medtronic, a leading global medical technology company, as the primary investor. The financing, announced on April 19, 2026, also saw participation from existing investors including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures, alongside new investors such as HSG and other notable global entities. This funding is intended to bolster Pulnovo's growth initiatives in the treatment of Pulmonary Hypertension and Heart Failure, areas that are increasingly critical in the medical technology sector.

Pulnovo Medical, recognized for its innovative therapies, has developed the proprietary Pulmonary Artery Denervation (PADN) System. This first-in-class, minimally invasive therapy addresses the overactive sympathetic nerve activity that contributes to pulmonary vascular remodeling and the progression of cardiopulmonary diseases. The company has successfully performed approximately 1,500 PADN procedures globally and has secured regulatory approvals across seven countries. With a focus on expanding its international footprint, Pulnovo is advancing its commercialization efforts in the European Union, the Middle East, and China, while also seeking to navigate the regulatory landscape in the United States, where it has received FDA Breakthrough Device designation.

The strategic partnership with Medtronic is expected to enhance Pulnovo's capabilities in clinical development and regulatory submissions, as well as facilitate international commercialization efforts. The collaboration is designed to leverage Medtronic's extensive global commercialization expertise, which could significantly expedite Pulnovo's market entry and growth. Additionally, the financing will support ongoing clinical trials, including the PULSE-LHD IDE trial in the U.S., which aims to further validate the clinical efficacy of the PADN System.

As the medical technology sector continues to evolve, investments in innovative therapies like those offered by Pulnovo Medical are indicative of a broader trend towards addressing unmet medical needs in chronic conditions such as heart failure and pulmonary hypertension. The growing focus on minimally invasive procedures and the integration of advanced technologies in patient care are reshaping treatment paradigms, emphasizing the importance of strategic partnerships in driving innovation and market access.

Looking ahead, the successful completion of this financing round positions Pulnovo Medical favorably within the competitive landscape of medical technology. The influx of capital not only strengthens its operational capabilities but also enhances its strategic alliances, paving the way for future growth and expansion. As the company continues to develop its proprietary technology and expand its clinical footprint, it is well-positioned to make a significant impact in the treatment of cardiopulmonary diseases, ultimately improving patient outcomes on a global scale.